Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.39 |
| ▸ | FABP7 | O15540 | 1/20 | 0.36 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 3/20 | 0.34 |
| ▸ | CA2 | P00918 | 3/20 | 0.34 |
| ▸ | CA12 | O43570 | 2/20 | 0.34 |
| ▸ | CA9 | Q16790 | 2/20 | 0.34 |
| ▸ | NAAA | Q02083 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 3/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11194073 | 0.82 | EPHX1 (0.45) | EPHX1FABP7FABP5CYP2C19CA1 | |
| SCHEMBL29353235 | 0.82 | EPHX1 (0.45) | EPHX1FABP7FABP5CYP2C19CA1 | |
| SCHEMBL11190659 | 0.82 | EPHX1 (0.45) | EPHX1FABP7FABP5CYP2C19CA1 | |
| SCHEMBL11188748 | 0.80 | EPHX1 (0.42) | EPHX1FABP7FABP5CYP2C19CA1 | |
| SCHEMBL5608543 | 0.79 | SMN1; SMN2 (0.39) | CYP2C19CA1CA2CA12CA9 | |
| SCHEMBL14422678 | 0.77 | FABP7 (0.45) | EPHX1FABP7FABP5CYP2C19CA1 | |
| SCHEMBL14966797 | 0.77 | EPHX1 (0.43) | EPHX1FABP7FABP5CYP2C19CA1 | |
| SCHEMBL5608583 | 0.76 | ALDH1A1 (0.33) | EPHX1CA1CA2CA12CA9 | |
| SCHEMBL29018107 | 0.76 | SUCNR1 (0.46) | EPHX1FABP7FABP5CYP2C19CA1 | |
| SCHEMBL5608576 | 0.75 | GAA (0.36) | EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7169944-B2 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2007-01-30 | — | — | US | disclosed |
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | TOSOH CORPORATION (JP) | 2004-04-01 | — | — | US | disclosed |
| EP-1403260-A2 | Optically active epoxy compounds and processes for their production | Tosoh Corporation (JP) | 2004-03-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063979-A1 | Optically active epoxy compounds and processes for their production | CYP51A1, CYP11B1, PTGES | EPHX1 47/4885FABP7 4270/4885FABP5 3563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.